酸纳米颗粒的构建,以有效地缓解性结肠炎
Shumeng Hu1,2, Runan Zhao1,3, Tao Chen1,4
1College of Food Science and Engineering, Jilin Agricultural University, Changchun, 130118, PR China. zhubeiwei@163.com.
Food & function
|August 19, 2024
概括
酸纳米颗粒 (CA NPs) 提高了酸 (CA) 的生物可用性和稳定性,用于治疗性结肠炎 (UC). 在UC模型中,CA NPs有效降低了炎症并恢复了肠道屏障.
科学领域:
- 胃肠病学 胃肠病学
- 纳米技术纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 性结肠炎 (UC) 涉及肠道炎症,氧化应激和屏障功能障碍.
- 酸 (CA) 显示了UC的治疗潜力,但其生物可用性和稳定性不佳.
研究的目的:
- 开发酸纳米粒子 (CA NPs),以提高CA的生物利用性和稳定性.
- 在性结肠炎的小鼠模型中评估CANP的疗效.
主要方法:
- 酶催化聚合被用来合成CA NPs.
- 分析了纳米粒子大小,细胞吸收和结肠组织保留.
- 用CANP治疗DSS诱导的UC小鼠,以评估治疗效果.
主要成果:
- CA NPs显示出最佳的纳米尺寸 (106.65 ± 4.12 nm) 和增强的细胞吸收.
- CA NPs在炎症的结肠组织中被长时间保留,使得向性UC治疗成为可能.
- CA NPs显著降低了UC症状,炎症和氧化应激,同时恢复了肠道屏障.
结论:
- 在UC治疗中,CA NPs代表了一种新的策略,以提高CA的生物利用性和稳定性.
- 这种纳米粒子方法为性结肠炎的预防和管理提供了一个有希望的治疗途径.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
131
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
131
Peptic Ulcer Disease IV: Management
78
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
78
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
377
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
377
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
417
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
417
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
103
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
103
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
358
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
358


